The cytokine interferon-γ (IFNγ) is a central coordinator of innate and adaptive immunity, but its highly pleiotropic actions have diminished its prospects for use as an immunotherapeutic agent. Here, we took a structure-based approach to decoupling IFNγ pleiotropy. We engineered an affinity-enhanced variant of the ligand-binding chain of the IFNγ receptor IFNγR1, which enabled us to determine the crystal structure of the complete hexameric (2:2:2) IFNγ-IFNγR1-IFNγR2 signalling complex at 3.25 Å resolution. The structure reveals the mechanism underlying deficits in IFNγ responsiveness in mycobacterial disease syndrome resulting from a T168N mutation in IFNγR2, which impairs assembly of the full signalling complex. The topology of the hexameric complex offers a blueprint for engineering IFNγ variants to tune IFNγ receptor signalling output. Unexpectedly, we found that several partial IFNγ agonists exhibited biased gene-expression profiles. These biased agonists retained the ability to induce upregulation of major histocompatibility complex class I antigen expression, but exhibited impaired induction of programmed death-ligand 1 expression in a wide range of human cancer cell lines, offering a route to decoupling immunostimulatory and immunosuppressive functions of IFNγ for therapeutic applications.
The type II interferon IFNγ is a potent immunomodulatory cytokine with many pleiotropic effects on the innate and adaptive immune systems due to the broad expression of its receptors on immune cells 1 . IFNγ exhibits an array of immunostimulatory, immunosuppressive, anti-proliferative and antiviral activities that are vital to normal immune homeostasis, and has a key role in tumour surveillance 2 . Among the most important actions of IFNγ are activating macrophages and dendritic cells, and inducing upregulation of major histocompatibility complex (MHC) molecules to enhance presentation of bacterial, viral and tumour antigens 3 . However, despite its central role in many important functions related to disease, IFNγ has not achieved therapeutic utility owing to its pleiotropy and counterbalancing immunostimulatory and immunomodulatory activities 4 . IFNγ is a homodimer 5 ; it engages two α-receptor chains, IFNγR1, which are constitutively expressed on all nucleated cells, and two β-receptor chains, IFNγR2, the expression of which is tightly regulated [6] [7] [8] . A structure of IFNγ in complex with IFNγR1 9 revealed the mode of binding of the high-affinity receptor subunit. However, the structure of the complete extracellular hexameric (2:2:2 IFNγ-IFNγR1-IFNγR2) signalling complex has not been solved, principally because of the extremely low affinity of the IFNγR2 subunit within the complex. Determination of the structure of the complete signalling complex is important for understanding IFNγ signalling and the mechanism of receptor-complex assembly, and for providing a blueprint for cytokine engineering to access the full therapeutic potential of IFNγ in cancer and immune diseases. Here, we have taken a receptor engineering approach to stabilize the complete IFNγ receptor complex, which has enabled structure determination and subsequent design of biased agonists.
Stabilization of the IFNγ receptor complex
When considering the assembly of the complete complex, it was important to know whether IFNγ drives the association of the receptors to form the signalling complex, or whether IFNγR1 and IFNγR2 are pre-dimerized, as some studies have suggested 10, 11 . We used two-colour single-molecule co-tracking to quantify binding of IFNγR1 and IFNγR2 in the plasma membrane [12] [13] [14] . By monitoring dimerization of individual receptors on a cell, we found that IFNγR1 and IFNγR2 co-track only on addition of IFNγ (Fig. 1a, b) . Similarly when monitoring either IFNγR1 or IFNγR2 binding steps, receptor dimerization was demonstrated to be a ligand-driven event (Extended Data Fig. 1a-c) .
We expressed IFNγR1 on the surface of yeast cells and showed that IFNγR2 only binds to the preformed IFNγR1-IFNγ complex, but not IFNγ alone. This implied that a composite binding surface is formed between IFNγR1 and IFNγ, which subsequently engages IFNγR2 (Extended Data Fig. 1d ). We sought to use this readout of cooperativity to engineer and select for a stabilized interaction with IFNγR2 (Fig. 1c) . First, we generated an IFNγR1 library using a non-biased error-prone approach with approximately three mutations created in each gene copy, to select for IFNγR1 variants with improved affinity. Second, we used gene shuffling of the first-generation IFNγR1 variants to further select for higher affinity ( Fig. 1d and Extended Data Fig. 1e) . After a single round of selection, the highest-affinity IFNγR1 variant was IFNγR1 F05, which contains six mutations ( Fig. 1e and Extended Data Fig. 1e ). The two most common mutations among the selected clones were located in the D2 FNIII domain of IFNγR1 in an area commonly observed forming receptor-receptor, or 'stem' contacts in other dimeric cytokine-receptor complexes 15 ( Fig. 1f) .
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Structure of the IFNγ receptor complex
We obtained crystals of the deglycosylated and fully glycosylated IFNγ receptor complexes (Extended Data Fig. 2a ), which diffracted to 3.25 Å and 3.8 Å resolution, respectively, and determined the structures by molecular replacement using previously determined structures of the 2:2 IFNγ-IFNγR1 intermediate complex (Protein Data Bank (PDB): 1FG9) 16 and IFNγR2 (PDB: 5EH1) 17 (Extended Data Table 1 ). The complete 2:2:2 IFNγ receptor complex is star-shaped with a two-fold symmetry imposed by the IFNγ homodimer (Fig. 2a) . The structure reveals six total interaction sites: two site 1 interfaces shared between IFNγ and IFNγR1, two site 2 interfaces shared between IFNγ and IFNγR2, and two site 3 interfaces shared between IFNγR1 and IFNγR2. IFNγR2 binds to the composite interface formed by the high affinity IFNγ-IFNγR1 interaction, which enables IFNγR2 to contact the open face of IFNγ site 2, as well as make extensive stem contacts with IFNγR1 site 3 (Fig. 2a) . Each of the two site 2 interfaces of IFNγ presents a concave surface that buries a total area of 1,243 Å 2 formed by helices A, D and E, and the N terminus of the cytokine (Figs. 2a, 3a, b) . In contrast to the site 1 interfaces, in which both chains of IFNγ form the IFNγR1 binding interfaces, only one IFNγ chain is needed to form each IFNγR2 binding site in the site 2 interface. IFNγR2 binds to IFNγ principally through a cluster of aromatic residues in loop 3 (F67, Y69 and F75) and through F109 in loop 4 of IFNγR2, which insert into a small pocket formed by helices A and D of IFNγ (Fig. 3b , left, and Extended Data  Fig. 2b ). The site 3 stem interfaces (1,469 Å 2 of total buried surface area) consist of primarily flat surfaces between IFNγR1 and IFNγR2 that interact through extensive van der Waals interactions (Figs. 2a, 3a, b) . IFNγR1 F05 contains two mutations, M161K and Q167K, located at the site 3 interfaces (Fig. 3b, right) . IFNγR1(M161K) shares a hydrogen bond with T149 of IFNγR2, and IFNγR1(Q167K) forms a salt bridge with D164 of IFNγR2; both interactions are likely to contribute to the stabilization of the site 3 interfaces (Fig. 3b , right, and Extended Data Fig. 2b) .
Although the IFNγ signalling complex is 'doubled' into a 2:2:2 hexamer (compared to typical 1:1:1 trimeric cytokine-receptor complexes 15 ) because of the homodimeric nature of the ligand, each 1:1:1 half of the hexamer shares structural similarities with the type III IFN trimeric (1:1:1) IFNλ receptor complex (PDB: 5T5W) (Fig. 2b) , including the relative binding modes of the high (IFNλR1) and low (IL-10Rβ) affinity receptors binding to one end of the helical bundle of the respective cytokines 15 (Fig. 2b) . By contrast, the IFNγ complex uses a structural paradigm that is distinct from the trimeric (1:1:1) type I IFN complex in both the relative geometries of the ligand-receptor complexes and the mode of binding to each receptor (Fig. 2c) .
Role of the neoglycan in IFNγR2(T168N) to MSMD
Lack of IFNγ responsiveness in mycobacterial disease syndrome (MSMD) has been attributed to a homozygous T168N mutation in IFNγR2
18
, which results in a life-threatening predisposition to mycobacterial infections 10 . The structure of the complete complex provides further insight into the molecular basis of this disease-associated mutation in IFNγR2. The structure places T168N (IFNγR2) directly at the site 3 interface (Fig. 3c) . The additional steric bulk that would result Article reSeArcH from the addition of an N-linked glycan at this site would introduce steric clashes, and is thereby likely to prevent IFNγR2 from docking to the high affinity 2:2 IFNγ-IFNγR1 intermediate complex. We used two approaches to test the hypothesis that glycosylation at the T168N position of IFNγR2 prevents docking with the 2:2 IFNγ-IFNγR1 intermediate complex. We produced a recombinant form of the neoglycan mutant IFNγR2(T168N) extracellular domain and verified that it was glycosylated at the T168N position with almost quantitative occupancy ( Fig. 3d and Extended Data Fig. 3 ). Using surface plasmon resonance (SPR), we measured the affinity of either wild-type IFNγR2 (Fig. 3e,  left) or the neoglycan mutant IFNγR2(T168N) (Fig. 3e, right) for IFNγ-IFNγR1. We detected a loss of binding between IFNγR2(T168N) for IFNγ-IFNγR1. In a second approach, we used single-molecule dimerization assays to quantify binding of the IFNγ receptors in the plasma membrane on addition of the ligand (Fig. 3f) . Binding of IFNγR1 is maintained, whereas IFNγR2(T168N) is not recruited to the complex following addition of IFNγ (Fig. 3f) . Thus, we propose that the molecular basis for the effect of the T168N mutation in mycobacterial disease syndrome is principally that the neoglycan sterically prevents IFNγR2(T168N) from engaging the IFNγ-IFNγR1 complex to complete the signalling complex.
Structure-guided design of partial agonists
The structure of the IFNγ signalling complex provides a topological blueprint for probing the signalling properties of intermediates in the assembly pathway to the hexameric complex (Fig. 4a) . We designed partial agonists by first engineering a version of IFNγ that retains binding to IFNγR1 but abrogates binding to IFNγR2 (Extended Data  Fig. 4a, b) . On the basis of our structure, we rationally designed the IFNγ(K74A/E75Y/N83R) triple mutant and confirmed loss of measurable binding to IFNγR2 by SPR (Extended Data Fig. 4a, b) . Using our knowledge of the site 2-specific mutations, we engineered 'asymmetric' single-chain mutants to selectively control receptor occupancy at either one or both IFNγR2 binding sites of IFNγ by expressing the molecules as single-chain fusions, in which, for example, only one chain of IFNγ contained a mutated binding site, and the other was wild-type IFNγ (Extended Data Fig. 5 ). Using this linker strategy, together with different combinations of site 1 19,20 and site 2 mutations, we created a panel of partial agonists that control both the number and location of the receptors in the complex (Extended Data Fig. 5b ), and characterized receptor-binding stoichiometry and oligomerization of the asymmetric variants by size-exclusion chromatography (SEC) (Extended Data Fig. 5c -e), and measured receptor dimerization and phosphorylated STAT1 (pSTAT1) signalling (Fig. 4b, c and Extended Data Fig. 4c, d ).
We observed that there was a relationship between the number and location of receptors bound and the maximal pSTAT1 signal, E max . The 2:2 IFNγ-IFNγR1 complex (using IFNγ variant 3, termed GIFN3) exhibits a 25% pSTAT1 E max , whereas addition of only 1 copy of IFNγR2, to create a 2:2:1 IFNγ-IFNγR1-IFNγR2 intermediate complex (using IFNγ variant 1, termed GIFN1), results in 100% pSTAT1 E max compared to the complete hexameric complex (Fig. 4a, c) . The second copy of IFNγR2 therefore appears to be functionally redundant; this also demonstrates the extreme sensitivity of IFNγ responsive cells to expression levels of IFNγR2. Of note, the 2:1:1 complex (using IFNγ variant 2, termed GIFN2) of IFNγ-IFNγR1-IFNγR2 exhibits a 50% E max for pSTAT1, and appears to be 'capped' until a third receptor subunit binds (using IFNγ variant GIFN1) (Fig. 4a, c) .
Biased agonists decouple IFNγ gene expression
We carried out gene expression studies of wild-type IFNγ and GIFN variants. We treated A549 cells, a lung carcinoma cell line, with either wild-type IFNγ or GIFN variants, and measured gene expression by next-generation sequencing using an AmpliSeq panel of more than 20,000 genes. Overall, we observe a general trend of the partial agonists inducing lower levels of gene expression in accordance with their pSTAT1 E max potencies (Fig. 4d, e) . However, we find that a subset of genes exhibit discordant, biased expression patterns (Fig. 4f, g ). For example, CD274, more commonly known as programmed death ligand 1 (PD-L1), is one of a subset of tunable genes, the expression of which is greatly reduced in response to the partial agonists (Fig. 4g,  top) , whereas MHC class I remains highly expressed (Fig. 4g, bottom  panel) .
We measured induction of surface expression of MHC class I and PD-L1, and cytokine secretion in response to wild-type IFNγ or GIFN variants (Fig. 5a, b and Extended Data Fig. 4e, i) . The partial agonists retained nearly wild-type levels of activity in inducing upregulation of MHC class I in A549 cells and purified human dendritic cells, but induction of PD-L1 expression by the partial agonists was greatly reduced (Fig. 5a, b and Extended Data Fig. 4f ). The GIFNs exhibited bias, with up to approximately 50-fold difference between induction of MHC I and PD-L1 in A549 cells, and similarly for dendritic cells, monocytes, and macrophages (Extended Data Fig. 4g, h ). We screened an additional six cancer cell lines, including Hap1, MeWo, HT-29, Hep G2, HeLa and Panc-1 cell lines, finding that the partial agonists Relative MFI (anti-PD-L1) Article reSeArcH consistently decouple MHC I:PD-L1 expression to different degrees depending on the cell line (Fig. 5c, d ).
The uncoupling of MHC I and PD-L1 expression shows that the partial agonists are also biased agonists that have uncoupled an important pleiotropic activity of IFNγ and, more broadly, that different genes downstream of IFNγ may exhibit different thresholds of activation that can be exploited by structure-based partial and/or biased agonists. This uncoupling of PD-L1 and MHC I expression is potentially of interest in the context of immunotherapy, as these IFNγ variants could enhance presentation of tumour antigens without the concomitant immunosuppression through checkpoint expression that occurs in response to wild-type IFNγ.
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MEthodS
Evolution of IFNγR1 on yeast. IFNγR1 was displayed on yeast as previously described 15, 22 . Staining and selection were performed using streptavidin-Alexa Fluor 647-labelled IFNγR2 with separation of the receptor-yeast population with anti-Alexa Fluor 647 antibody labelled with paramagnetic microparticles. Unlabelled IFNγ (750 nM) was present as a saturating condition during all selections. Expression on the yeast surface was assayed by staining with a Myc-tagged antibody conjugated to Alexa Fluor 647 (Cell Signaling). Progression of the enrichment was monitored by staining the receptor on yeast and analysis by flow cytometry (BD Accuri). Error-prone PCR and DNA shuffling 15, 23 , and 96-well screening were used for engineering IFNγR1 as previously described 15 . Protein expression, purification, and structural determination. IFNγ and signalling variants were expressed in the Hi5 insect expression system (Invitrogen BTI-TN-5B1-4), and purified as previously described 21 . For crystallization, IFNγ was expressed in the presence of kifunensine. IFNγ DN (K74A, E75Y, and N83R) and related variants were synthesized (Operon) and cloned into the insect expression plasmid. Asymmetric variants were expressed with three tags, allowing for their expression and purification. An 8× His tag at the C terminus was used at the first step of purification from the insect secreted medium. In the second step, rhinovirus 3C protease was used to cleave the encoded 3C linker between the two hetero subunits of the asymmetric IFNγ proteins. After cleavage, the proteins were further purified using a protein C tag encoded at the N terminus and a second 8× His purification to isolate the heterodimeric IFNs. Their receptor binding properties were validated by SEC by injecting 200 μg of each IFNγ alone, in combination with equimolar quantities of IFNγR1, or with IFNγR1 and IFNγR2. IFNγR1 and IFNγR2 were expressed in HEK293S GnTI − cells (ATCC CRL-3022) that were transduced by lentivirus 24 encoding each receptor. For glycan-shaved complexes, IFNγ, IFNγR1 F05, and IFNγR2 were deglycosylated by treatment with EndoF and EndoH overnight at 4 °C. Both the deglycosylated and the glycosylated proteins were mixed in equimolar ratios and digested with carboxypeptidase A and B before co-purification by SEC on a Superdex 200 column (GE). The final protein concentration of the glycosylated and deglycosylated complex used in the crystallization screen was 10 mg/ml. Crystals of the deglycosylated complex were obtained within 24 h at 20 °C from the MCSG3 (Anatrace) in the screen condition containing 0.1 M bis-tris propane:HCl, pH 7, 2 M sodium formate. Crystals were cryoprotected by the addition of ethylene glycol to 25%. Diffraction data were collected at 100 K at the Stanford Synchrotron Radiation Lightsource beamline 12-2 to 3.25 Å resolution, using X-rays of wavelength 0.97946 Å. For the glycosylated complex, crystals were grown at 20 °C from the MCSG2 screen in 1.1 M ammonium tartrate dibasic, pH 7.0. Crystals were cryoprotected with 25% ethylene glycol, and diffraction data were acquired at 100 K at the Advanced Light Source beamline 8.2.2 to 3.8 Å resolution using X-rays of wavelength 0.999989 Å.
Data for both structures were processed in XDS 25 . The structure of the shaved complex was solved by molecular replacement in Phaser 26 using models of IFNγ and IFNγR1 from PDB ID 1FG9 and IFNγR2 from PDB ID 5EH1. Iterative cycles of rebuilding and refinement were performed using Coot 27 , Phenix 28, 29 , and Buster 30 using individual atomic B-factors, torsional NCS restraints, and automatically determined TLS groups 31 . Ligand atoms in the deglycosylated structure include ethylene glycol that was present from the cryoprotectant, glycan residues that remained after digestion of the protein with EndoH, and peaks adjacent to Cys174 on the surface of IFNγR2 that were modelled as disulfide-bound cysteines. Mindful of the low resolution of our data, all heteroatoms were built into mF o − DF c peaks >3σ and assessed after refinement for appropriate hydrogen-bond or disulfide-bond geometry, lack of clashes, and density in the resulting 2mF o − DF c map. The high resolution limit for the final round of refinement was 3.25 Å, chosen by performing paired refinement tests with d min of 3.1, 3.25 and 3.4 Å resolution as described 32 . The final model has 97.47% of residues in favoured regions of the Ramachandran plot with zero outliers. The structure of the glycosylated complex was solved by molecular replacement using the refined shaved complex as a search model. Iterative cycles of rebuilding and refinement were performed using Coot and Phenix using torsional NCS restraints, grouped B-factors, and per-chain TLS. To assess our choice of resolution cut-off, we performed paired refinements as above using d min values of 3.6, 3.8, 4.0 and 4.2 Å, and we selected a 3.8 Å resolution limit for our final refinement. The final structure has 97.39% of residues in favoured regions of the Ramachandran plot with zero outliers. In both structures, partial disorder of one copy of IFNγR2 required the use of NCSaveraged maps for rebuilding. Structure quality was assessed using Molprobity 33 . Surface plasmon resonance. A GE Biacore T100 was used to measure the K D by equilibrium methods. Approximately 100 response units (RU) of IFNγR1 was captured on a SA-chip (GE Healthcare), including a reference channel of an unrelated cytokine receptor (IL-2Rβ). The saturating concentration for both wild-type IFNγ or IFNγ(K74A/E75Y/N83R) was 50 nM and was present in all dilutions of IFNγR2 or IFNγR2(T168N).
Mass spectrometry analysis of IFNγR2(T168N) neo N-glycosylation site.
Approximately 1 μg of purified, recombinant human IFNγR2(T168N) expressed in HEK293S GnTI − (ATCC CRL-3022) cells was denatured and reduced in 8 M urea containing 20% ammonium bicarbonate and 10 mM tris(2-carboxyethyl) phosphine (Thermo Fisher Scientific), then subsequently alkylated with iodoacetamide. After fourfold dilution, the protein was enzymatically digested with chymotrypsin overnight at 37 °C. The resulting digest was then subjected to a C 18 Zip-Tip filter clean-up and eluted using 50% acetonitrile, 0.1% formic acid, and filtered through a 0.2-μm nylon spin filter for high-quality peptide purification. A portion of the purified peptides were diluted to 20% acetonitrile and 0.1% formic acid, and 5 μl of ~2ng/μl digests was injected into a Q-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific) equipped with an Easy nano-LC HPLC system with a C18 EasySpray PepMap RSLC C18 column (50 μm × 15 cm, Thermo Fisher Scientific). Separation of (glyco)peptides was performed with a 30-min binary gradient consisting of solvent A (0.1% formic acid in water) and solvent B (90% acetonitrile and 0.1% formic acid in water) with a constant flow rate of 300 nl/min. Spectra were recorded with a resolution of 35,000 in the positive polarity mode over the range of m/z 350-2,000 and an automatic gain control target value of 1 × 10 6 . The 10 most prominent precursor ions in each full scan were isolated for higher energy collisional dissociation-tandem mass spectrometry (HCD-MS/MS) fragmentation with normalized collision energy of 27%, an automatic gain control target of 2 × 10 5 , an isolation window of m/z 3.0, dynamic exclusion enabled, and fragment resolution of 17,500. Raw data files were analysed using Proteome Discoverer v.2.1.0.81 (Thermo Fisher Scientific) with Byonic v.2.10.5 (Protein Metrics) as a module for automated identification of (glyco)peptides. EICs of all identified (glyco)peptides were generated using Xcalibur v.4.0.27.19 (Thermo Fisher Scientific).
Decoupling of MHC I:PD-L1 expression in cancer and immune cells.
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors, who provided written informed consent for research protocols approved by the Stanford Institutional Review Board. Human blood dendritic cells and monocytes were enriched from blood in leukoreduction system chambers by Ficoll-Hypaque density gradient centrifugation. For monocyte enrichment, blood was preincubated with RosetteSep Human Monocyte Enrichment Cocktail (StemCell Technologies). White blood cells were removed and monocytes were isolated with EasySep Human CD14 Positive Selection Kit II (StemCell Technologies). For macrophage differentiation, monocytes were cultured for 6 days in chRPMI (RPMI 1640 (Thermo Fisher Scientific), 10% human serum and 100 U/ml penicillin-streptomycin (GIBCO) and 50 ng/ml recombinant human M-CSF (Peprotech). Dendritic cells were enriched using the EasySep Human Myeloid DC Enrichment kit (19061; StemCell Technologies). The dendritic-cell-enriched samples were stained with DAPI and lineage markers CD19-PE-Cy5 (Beckman Coulter); CD56-FITC, CD3-Alexa700 (Biolegend); CD11c-PE-Cy7, HLA-DR v500, CD14-APC-H7 (BD); and CD304-PE (MACs Miltenyi Biotech). Dendritic cells were sorted on a BD FACsAria II as HLA-DR
+
CD11c
+ cells, which were negative for all other lineage markers. Monocytes, macrophages and dendritic cells were stimulated in chRMPI for 18 or 48 (dendritic cells) hours and harvested using PBS with 5 mM EDTA or Accutase (Fisher Scientific). A549 cells (ATCC CCL-185) were cultured at 37 °C in 5% CO 2 and RPMI 1640 (Thermo Fisher Scientific) containing 10% FBS and 100 U/ml penicillin-streptomycin (GIBCO). Cells were plated into 48-well plates, and stimulated for 48 h with various concentrations of protein and harvested using 0.25% trypsin-EDTA (GIBCO). Cells were analysed by flow cytometry using an LSR II (BD). Dead cells were discriminated using the Live/Dead Aqua Fixable Dead Cell Stain Kit (Invitrogen), non-specific antibody binding was minimized using Human F C Block (BD) and surface staining was performed with PE-Dazzleconjugated anti-PD-L1 (clone 29E.2A3, Biolegend) and v450-conjugated anti-HLA-ABC (clone G46-2.6, BD). The MFI change was calculated by subtracting the MFI of non-stimulated controls from the MFI of stimulated samples, relative to wild-type IFNγ. The relative MHC I:PD-L1 ratio was calculated by dividing the MFI ratios for MHC I that for PD-L1. For screening of cancer cell lines other than A549 cells (ATCC CCL-185), Hap1 (NKI-AVL), MeWo (ATCC HTB-65), Hep G2 (ATCC HB-8065), HT-29 (ATCC HTB-38), Panc-1 (ATCC CRL-1469) or HeLa (ATCC CCL-2) cells were plated in 96-well format, treated with different concentrations of wild-type IFNγ or GIFNs for 24 h, and MHC I:PD-L1 ratios were quantified as previously detailed. For quantification of gene expression by RTqPCR and next-generation sequencing, 600,000 cells were plated in a 6-well format and treated with proteins for 48 h. RNA was extracted (RNeasy Micro Kit, Qiagen), 1.5 μg of this RNA was then used for RT-qPCR (High Capacity RNA-to-cDNA Kit, Applied Biosystems), and measured by quantitative PCR (qPCR) (PowerSYBR Green PCR Master Mix, Applied Biosystems) on a QuantStudio 3 instrument (Applied Biosystems) according to the manufacturer's instructions. Primers were purchased from (Operon) for 18S (fwd 5′GTAACCCGTTGAACC CCATT3′, rev 5′CCATCCAATCGGTAGTAGCG3′), HLA-A (fwd 5′CCAGGTAGG CTCTCAACTG3′, rev 5′CCAGGTAGGCTCTCAACTG3′), HLA-B (fwd Article reSeArcH 5′AACCGTCCTCCTGCTGCTCTC3′, rev 5′CTGTGTGTTCCGGTCCCA ATAC3′), PD-L1 (fwd 5′TGGCATTTGCTGAACGCATTT3′, rev 5′TGCAGCCAG GTCTAATTGTTTT3′). Expression of over 20,000 human genes was measured by next-generation sequencing using the Ion AmpliSeq Human Gene Expression kit (Thermo Fisher). Samples were loaded on a 550 chip and sequenced on an Ion S5 XL sequencer (Thermo Fisher). RNA samples from two biological qPCR experiments were used for sequencing. Samples were barcoded following manufacturer protocols and were as follows: untreated-A (fwd 5′CTAAGGTAAC3′), wild-type-A (fwd 5′TAAGGAGAAC3′), GIFN2-A (fwd 5′AAGAGGATTC3′), GIFN3-A (fwd 5′TACCAAGATC3′), GIFN4-A (fwd 5′CAGAAGGAAC3′), untreated-B (fwd 5′CTGCAAGTTC3′), wild-type-B (fwd 5′TTCGTGATTC3′), GIFN2-B (fwd 5′TTCCGATAAC3′), GIFN3-B (fwd 5′TGAGCGGAAC3′) and GIFN4-B (fwd 5′CTGACCGAAC3′). Gene mapping and analysis was performed using Ion Torrent Suite v.5.10.0 (Thermo Fisher). Heat maps and figures showing PCA of gene expression were generated in MATLAB v.R2018b (MathWorks). On-cell receptor dimerization. Receptor homo-and heterodimerization was quantified by two-colour single-molecule co-tracking as described previously 34, 35 . For quantifying receptor heterodimerization, IFNγR1 and IFNγR2 N-terminally fused to variants of monomeric GFP were co-expressed in HeLa cells and labelled using anti-GFP nanobodies Enhancer and Minimizer, respectively. For quantifying homodimerization, GFP-tagged IFNγR1 or IFNγR2 were expressed and labelled with two different colours. Time-lapse dual-colour imaging of individual IFNγR1 and IFNγR2 in the plasma membrane was carried out by total internal reflection fluorescence microscopy with excitation at 561 nm and 640 nm and detection with a single EMCCD camera using an image splitter. Molecules were localized using the multiple-target tracing (MTT) algorithm 36 . Receptor dimers were identified as molecules that co-localized within a distance threshold of 100 nm for at least 10 consecutive frames. pSTAT1 signalling and bead-based immunoassay cytokine secretion. Hap1 cells (NKI-AVL) were plated in a 96-well format and treated with either wildtype IFNγ or partial agonists at varying concentrations for 15 min at 37 °C. The medium was removed and cells were detached with Trypsin (Gibco) for 5 min at 37 °C. Cells were transferred to a deep-well 96-well block containing 10% paraformaldehyde (PFA) by volume and incubated for 15 min at room temperature, washed three times with phosphate-buffered saline containing 0.5% (w/v) BSA (PBSA), resuspended with 100% methanol overnight, and stained with Alexa Fluor 488 conjugated anti-pSTAT1 antibody (Cell Signaling). The half-maximal response concentration (EC 50 ) and E max of signalling was determined by fitting the data to a sigmoidal dose-response curve (GraphPad Prism v.7). The bead-based immunoassay cytokine secretion assay was performed at the Human Immune Monitoring Center at Stanford University as previously described 37 No statistical methods were used to predetermine sample size. The experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment. P values were determined for the difference between wild-type and PHA control in the cytokine secretion experiments using the Student's t-test with a two-tail distribution of a two-sample heteroscedastic test. For the mass-spectrometry experiment, sequence coverage was determined by dividing the number of amino acids identified in the proteomic analysis (179 residues, highlighted in Extended Data Fig. 3b ) by the total number of amino acids in the protein (233). The confidence for identification of the peptides in the highlighted region is based on the Byonic algorithm as previously described 38 . Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
Structure factors and coordinates have been deposited in the Protein Data Bank with identification numbers 6E3K and 6E3L. Diffraction images have been deposited in the SBGrid Data Bank with dataset ID 591 and 592. Next-generation sequencing data files from the human transcriptome study were deposited to the NCBI Gene Expression Omnibus (GEO) data repository with accession number GSE122672. Other data and materials are available upon request from the corresponding author. underlined. This peptide was detected as a glycopeptide with several glycoforms as quantified in Fig. 3d . Mappings highlighted in green indicate high confidence with a false discovery rate (FDR) below 1% and yellow indicates a FDR of 1-5%. Carbamidomethyl (C) and glycosylation (G) sites are indicated above the site of modification. Confidence levels were determined as previously described 38 . c, MS2 spectra confirming that the ion used for the EICs shown in Fig. 3d is the peptide SSPFDIADNSTAF from IFNγR2(T168N) modified with a HexNAc 2 Hex 5 glycan attached to N168. The data shown are for a single experiment. Fig. 4 | Disrupting IFNγR2 binding Fig. 5 ). Data are mean ± s.e.m.; n is indicated over each bar; n refers to the number of biologically independent samples. d, STAT1 activation of GIFN4 in Hap1 cells. Curve was fit to a first-order logistic model. Data are mean; n = 2 biologically independent samples. e, Quantification of MHC class I expression by qPCR using primers against HLA chain b in A549 treated cells. Data are mean ± s.e.m.; n = 3 biologically independent experiments. f, Dendritic cells purified from whole blood were treated for 48 h with either wild-type IFNγ or the partial agonists for 48 h; these agonists upregulate MHC class I antigen expression as quantified by fluorescently labelled antibody (left) or PD-L1 (right). Data shown are for ligand concentrations of 0.1, 0.5, 2.5, 12.5 and 62.5 nM (left to right, respectively, for each agonist). Data are mean ± s.e.m.; n = 3 biologically independent experiments. g, Using the MHC class I and PD-L1 expression data (f and Fig. 5b ), the ratio of MHC I:PD-L1 induction was determined for each protein concentration relative to wild-type. Left, dendritic cells; right, A549 cells. Data are mean ± s.e.m.; n = 3 biologically independent experiments. h, Biased MHC I:PD-L1 expression for monocytes (right) and macrophages (left) isolated from PBMCs. Data as shown are for protein concentrations of 0.1, 0.5, 2.5, 12.5 and 62.5 nM (left to right, respectively, for each agonist). Data are mean ± s.e.m.; n = 6 independent samples. i, Cytokine secretion profile of IFNγ and partial agonists for PBMCs treated with 100 nM of each protein for 24 h. Shown are the mean expression of 36 secreted cytokines that are significantly different (P < 0.05) between the wild-type and PFA-treated control. Expression of IL-10, IL-12P70, IL-2, IP-10, MIG and IL-23 are indicated in text or asterisks aligned below the text. Data shown are for n = 2 biologically independent samples, each assayed in triplicate. P values were determined using the Student's t-test with a two-tailed distribution of a two-sample heteroscedastic test. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
Extended Data
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code Data collection Surface plasmon resonance was collected using the Biacore T100 control software version 2.0.4. Yeast binding data were collected with BD Accuri C6 software version 1.0.264.21. Size exclusion chromatography data were collected using UNICORN version 7.1. For surface marker expression experimentes, data were collected using FACSDiva version 8.0.2. Screen of additional cancer cell lines for biased marker expression were collected on a Beckman Coulter Cytoflex instrument with Cytoflex software version 2.0.
Next-generation sequencing of A549 IFNG treated cells to compare changes in the human transcriptome of over 20,000 genes was performed on an Ion S5 XL instrument with a 550 chip (Thermo Fisher). Transcript mapping and relative abundance was performed using Torrent suite version 5.10.0.
For mass spec, a Q-Exactive Orbitrap mass spectrometer (Thermo Fisher) equipped with an Easy nano-LC HPLC system with a C18 EasySpray PepMap RSLC C18 column (50 μm x 15 cm, Thermo Fisher Scientific) was used.
For on-cell receptor dimerization experiments, images were acquired using the OLYMPUS cellSens Dimensions 1.18 software.
Data analysis
Microsoft Excel (version 16) and Prism7 (version 7.0d) for Mac OsX were used for analyzing plotting the data from the binding, functional signaling, marker and gene expression, and cytokine secretion experiments. FlowJo version 10.4.2 was used for surface marker expression experiments. Sequence alignment was generated in Geneious version 6. SPR data were analyzed using the Biacore T100 evaluation software versino 2.0.4. qPCR data was analyzed using the RQ Thermo cloud app on Jul 19, 2018. Heatmap and principle component analysis of gene expression data was performed using Matlab version R2018b (Mathworks).
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Mass spec raw data files were analyzed using Proteome Discoverer v2.1 (Thermo Fisher Scientific) with Byonic v (Protein Metrics) as a module for automated identification of (glyco)peptides. Extracted ion chromatograms (EICs) of all identified (glyco)peptides were generated using Xcalibur v (Thermo Fisher Scientific). For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: All studies must disclose on these points even when the disclosure is negative.
Sample size
The variability of the effect size induced by the ligand was determined by performing three individual biological replicates. Experimental outliers were identified based on the controls, the experimental unit was in this case repeated, leading to sample sizes from (3-n).
Data exclusions Experiments were excluded if the controls indicated experimental problems e.g. negative data for the positive controls. Data points were excluded when there was a technical mistake in the ligand preparation or during the procedure of the experiment. Data exclusion was not pre-established.
Replication
The ligands have been tested in at least three individual biological replicates including preparation of the dilutions. All attempts of experimental replication were successful.
Randomization Plating of cells used in assays produces randomization. For cytokine secretion and surface marker expression, PBMCs were obtained from multiple donors at random.
Blinding
Blinding was not used for these studies. Engineering of the IFNg variants and pSTAT1 was performed in a single lab at Stanford. This information alone would not have predicted effects on surface expression of PD-L1 and MHC I which were performed by an independent laboratory.
Reporting for specific materials, systems and methods
The following cell lines from ATCC do not provide authentication/validation information: HEK293 GnTI-cells are from ATCC (CRL-3022), SF9 cells were from ATCC (CTL-1711), MeWo (ATCC HTB-65), Hep G2 (ATCC HB-8065), HT-29 (ATCC HTB-38), and Panc-1 (ATCC CRL-1469 
Mycoplasma contamination
All eukaryotic cell lines used for signaling and functional assays were tested negative for mycoplasma on a regular basis, before and during tissue culture.
Cell lines used for protein production were not tested for mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)
No ILAC listed cell lines that are commonly misidentified were used in this study.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation 
Software
The BD Accuri C6 software was used for collection and analysis of yeast and signaling experiments. For surface marker expression studies, FACSDiva was used for data collection and FlowJo was used for analyses.
Cell population abundance To ensure complete coverage of the library after each round of selection, the total number of yeast were calculated by the number of events by FACS. 10x the number of yeast were then carried grown for the next round of selection.
Dendritic cell purity post sort was assessed by flow cytometry and found to be 94% pure.
Gating strategy
For binding titrations and pSTAT1 on the analyzer, in fluorescent channels boundaries were set such that the positive gates included less than 0.3% of the samples described above.
PD-L1 and MHC I expression on A549 and DCs: A549 and dendritic cells were first gated based on FSC-A and SSC-A to exclude debris. Doublets were excluded by size by gating based on FSC-A vs FSC-H. Dead cells were excluded by staining with LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit. Positive and negative antibody staining boundaries were determined based on fluorescence minus one controls. Dendritic cells were selected as HLA-DR and CD11c positive; CD3, CD56, CD19, CD14 and CD304 negative.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
